Novel Methods and Pathways in Cancer Glycobiology Research (Advances in Cancer Research)

個数:

Novel Methods and Pathways in Cancer Glycobiology Research (Advances in Cancer Research)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 304 p.
  • 言語 ENG
  • 商品コード 9780323991773
  • DDC分類 616.994

Full Description

Cancer glycobiology is a blazing hot area of cancer research with aberrant post-translational glycosylations on lipids and proteins considered critical for cancer development and metastasis.  The NIH/NCI Alliance of Glycobiologists for Cancer Research is a consortium of (10) tumor glycobiology laboratories funded to investigate how cancer-associated glycans (CAG) impact the development and metastasis of cancer.  The hope of this momentous effort is to discover CAGs for use as novel biomarkers to detect early-stage cancer or its aggressive behavior or, alternatively, as novel molecular targets with the promise of a curative approach to cancer therapy.  The mission of the 'Alliance' is to study structure and function of CAGs in cancer development and to provide clinically useful biomarkers for detecting cancer early or the potential of metastasis.  This charge has stimulated extensive collaborations across US and International institutions to accelerate discovery of glycan-based biomarkers to the forefront of NCI's efforts to diagnose early-stage cancer and provide curative anti-cancer therapies. 

The main goals of these research efforts are:
1.  To identify and study how cancer-associated glycans functionally impact cancer growth and metastasis
2.  To identify cancer-associated glycans that can serve as biomarkers for the detection or progression of cancer
3.  To develop cancer-associated glycans as novel therapeutic targets for the treatment and cure of cancer

This volume consists of (9) chapters, one from each funded laboratory, that reviews new methods and mechanisms  highlighting glycoconjugates and their roles as cancer biomarkers and/or anti-cancer therapeutic targets.

Contents

1. The clinical role of glycobiology on ovarian cancer progression
Rhyisa Armbrister, Laura Ochoa, and Karen L. Abbott
2. Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach
Yehia Mechref, Wenjing Peng, Sakshi Gautam, Parisa Ahmadi, Yu Lin, Jianhui Zhu, Jie Zhang, Suyu Liu, Amit G. Singal, Neehar D. Parikh, and David M. Lubman
3. Beyond glyco-proteomics—Understanding the role of genetics in cancer biomarkers
Andrew DelaCourt, and Anand Mehta
4. Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
Nicholas M. Riley, Ru M. Wen, Carolyn R. Bertozzi, James D. Brooks, and Sharon J. Pitteri
5. Role of tumor cell sialylation in pancreatic cancer progression
Michael P. Marciel, Barnita Haldar, Jihye Hwang, Nikita Bhalerao, and Susan L. Bellis
6. The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma
Norhan B.B. Mohammed, Aristotelis Antonopoulos, Anne Dell, Stuart M. Haslam, and Charles J. Dimitroff
7. Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity
Giang Le Minh, and Mauricio J. Reginato
8. The biology of E-selectin ligands in leukemogenesis
Evan Ales, and Robert Sackstein
9. Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential
Hua Yang, and Lianchun Wang

最近チェックした商品